A Randomized Controlled Trial of Fresh Frozen Plasma for Coagulopathy in Russell's Viper (Daboia Russelii) Envenoming
Overview
Authors
Affiliations
Summary: Background Russell's viper (Daboia russelii) envenoming is a major health issue in South Asia and causes venom-induced consumption coagulopathy (VICC). Objectives To investigate the effects of fresh frozen plasma (FFP) and two antivenom doses in correcting VICC. Methods We undertook an open-label randomized controlled trial in patients with VICC at two Sri Lankan hospitals. Patients with suspected Russell's viper bites and coagulopathy were randomly allocated (1 : 1) to high-dose antivenom (20 vials) or low-dose antivenom (10 vials) plus 4 U of FFP. The primary outcome was the proportion of patients with an International Normalized Ratio (INR) of < 2 at 6 h after antivenom administration. Secondary outcomes included anaphylaxis, major hemorrhage, death, and clotting factor recovery. Results From 214 eligible patients, 141 were randomized: 71 to high-dose antivenom, and 70 to low-dose antivenom/FFP; five had no post-antivenom blood tests. The groups were similar except for a delay of 1 h in antivenom administration for FFP patients. Six hours after antivenom administration, 23 of 69 (33%) patients allocated to high-dose antivenom had an INR of < 2, as compared with 28 of 67 (42%) allocated to low-dose antivenom/FFP (absolute difference 8%; 95% confidence interval - 8% to 25%). Fifteen patients allocated to FFP did not receive it. Severe anaphylaxis occurred equally frequently in each group. One patient given FFP developed transfusion-related acute lung injury. Three deaths occurred in low-dose antivenom/FFP patients, including one intracranial hemorrhage. There was no difference in recovery rates of INR or fibrinogen, but there was more rapid initial recovery of factor V and FX in FFP patients. Conclusion FFP after antivenom administration in patients with Russell's viper bites did not hasten recovery of coagulopathy. Low-dose antivenom/FFP did not worsen VICC, suggesting that low-dose antivenom is sufficient.
Clinical Characteristics of Snakebite Envenomings in Taiwan.
Mao Y, Liu P, Lai K, Luo Y, Chen K, Lai C Toxins (Basel). 2025; 17(1).
PMID: 39852967 PMC: 11769513. DOI: 10.3390/toxins17010014.
Farajidana H, Mosalamiaghili S, Assadian K, Jahangiri S, Masumzadegan M, Sadeghi F Health Sci Rep. 2024; 7(10):e70135.
PMID: 39416345 PMC: 11480123. DOI: 10.1002/hsr2.70135.
The Chinese guideline for management of snakebites.
Lai R, Yan S, Wang S, Yang S, Yan Z, Lan P World J Emerg Med. 2024; 15(5):333-355.
PMID: 39290598 PMC: 11402871. DOI: 10.5847/wjem.j.1920-8642.2024.076.
[A global core outcome measurement set for snakebite clinical trials].
Abouyannis M, Esmail H, Hamaluba M, Ngama M, Mwangudzah H, Mumba N Med Trop Sante Int. 2023; 3(3).
PMID: 38094484 PMC: 10714599. DOI: 10.48327/mtsi.v3i3.2023.421.
Xie R, Ye X, Tang C, Wang Y, Zhong L J Toxicol. 2023; 2023:8832355.
PMID: 37168533 PMC: 10164868. DOI: 10.1155/2023/8832355.